Allorion Therapeutics is a small molecule therapeutic development company that focuses on cancer and autoimmune illnesses.
Allorion Therapeutics has raised $50.0M in total funding. The most recent round was Series B. The last funding was announced in March 2023.
Allorion Therapeutics's investors include Qiming Venture Partners, INCE Capital, IDG Capital, Octagon Capital Advisors, Med-Fine Capital.
Allorion Therapeutics is headquartered in Natick, United States.
Allorion Therapeutics is a small molecule therapeutic development company that focuses on cancer and autoimmune illnesses.
Allorion Therapeutics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Allorion Therapeutics — Funding & Investors." VCBacked, March 9, 2023, https://www.vcbacked.co/company/allorion-therapeutics. Accessed July 20, 2026.
VCBacked. (2023). Allorion Therapeutics — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/allorion-therapeutics
{{cite web |title=Allorion Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/allorion-therapeutics |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated